Your browser doesn't support javascript.
loading
Enhanced procoagulant activity of select hemophilia B causing factor IX variants with emicizumab.
Lee, Kyumin; Chau, Julia Q; Suber, Yani B; Sternberg, Anna R; Pishko, Allyson M; George, Lindsey A; Bhoj, Vijay G; Doshi, Bhavya S; Samelson-Jones, Benjamin J.
Afiliación
  • Lee K; Division of Hematology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA.
  • Chau JQ; Division of Hematology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA.
  • Suber YB; Division of Hematology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA.
  • Sternberg AR; Division of Hematology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA.
  • Pishko AM; Division of Hematology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  • George LA; Division of Hematology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA.
  • Bhoj VG; Division of Hematology, Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  • Doshi BS; Raymond G. Perelman Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA.
  • Samelson-Jones BJ; Department of Pathology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Blood ; 144(11): 1230-1235, 2024 09 12.
Article en En | MEDLINE | ID: mdl-38985830
ABSTRACT
ABSTRACT Emicizumab improves the procoagulant activity of select loss-of-function factor IX (FIX) variants with likely dysfunctional assembly of the intrinsic Xase complex, resulting in hemophilia B (HB). FVIII mimetics may represent an alternative nonfactor therapy for select patients with HB.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Factor IX / Hemofilia B / Anticuerpos Biespecíficos / Anticuerpos Monoclonales Humanizados Límite: Humans Idioma: En Revista: Blood Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Factor IX / Hemofilia B / Anticuerpos Biespecíficos / Anticuerpos Monoclonales Humanizados Límite: Humans Idioma: En Revista: Blood Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos